The curious case of Wuhan’s Institute of Virology and remdesivir

The Patent Law of the People’s Republic of China first went into effect on April 1, 1985. It has been amended three times with a fourth amendment scheduled to take effect on June 1, 2021.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

More features

Illumina ordered to recall products after German patent ruling

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

The curious case of Wuhan’s Institute of Virology and remdesivir

More on this story

Editor's picks

Editor's picks

More features